NHS BLOOD AND TRANSPLANT

Their core work

NHS Blood and Transplant is the UK's national blood, organ, and tissue service, responsible for managing the blood supply chain, organ donation, and transplant services across England. In research, they bring deep expertise in blood products, plasma therapies, and advanced cell-based treatments — from mesenchymal stem cell therapies for kidney disease and tracheal tissue engineering to convalescent plasma evaluation during COVID-19. Their H2020 involvement reflects a clinical translation focus: taking cell therapies and biological products from preclinical validation through to patient-ready treatments, with particular strength in safety assessment, quality standards, and large-scale biological product handling.

What they specialise in

How they've shifted over time

NHSBT's early H2020 work (2015–2017) centered on direct clinical translation of cell therapies — a Phase 1b/2a trial for diabetic kidney disease (NEPHSTROM) and tissue-engineered trachea development (TETRA), both focused on advanced therapy medicinal products (ATMPs). From 2018 onward, the focus broadened in two directions: upstream into preclinical assessment tools (RenalToolBox's imaging and tracking technologies) and laterally into pandemic-driven plasma science (SUPPORT-E). Their most recent and largest project (AMELIE) signals a return to clinical cell therapy, now targeting muscle cell anchoring for incontinence — a new therapeutic area for them.

NHSBT is expanding from pure clinical translation toward the assessment infrastructure that underpins cell therapies — making them increasingly valuable as a partner who can both develop and validate advanced biological treatments.

How they like to work

NHSBT participates exclusively as a consortium partner, never coordinating — consistent with a national health service body that contributes domain expertise and clinical infrastructure rather than driving research agendas. With 56 unique partners across 14 countries from just 5 projects, they operate in large, multinational consortia (averaging 11+ partners per project). This suggests they are a sought-after partner valued for their clinical translation capabilities and access to patient populations and biological materials at national scale.

NHSBT has collaborated with 56 distinct partners across 14 countries through 5 projects, indicating broad European reach and integration into major health research networks. Their consortia span Western and Northern Europe, reflecting the geography of advanced cell therapy and regenerative medicine research.

What sets them apart

NHSBT occupies a rare position as a national-scale blood and tissue service with active involvement in advanced cell therapy research — few organizations combine routine handling of millions of biological products with frontline regenerative medicine R&D. Their infrastructure for blood collection, processing, storage, and distribution at industrial scale is directly transferable to cell therapy manufacturing and quality assurance. For consortium builders, they offer something hard to replicate: clinical-grade biological material expertise, established regulatory pathways for ATMPs, and access to the UK's patient and donor networks.

Highlights from their portfolio

• AMELIE
  Largest single grant (EUR 1.8M) and their most recent project, targeting an entirely new therapeutic area — anchored muscle cells for faecal incontinence caused by obstetric trauma.
• SUPPORT-E
  Rapid-response COVID-19 project evaluating convalescent plasma quality across Europe, directly leveraging NHSBT's core national mandate in blood product standards.
• NEPHSTROM
  Phase 1b/2a clinical trial of mesenchymal stem cells for diabetic kidney disease — their earliest H2020 project and closest to direct patient treatment.